A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria

Inclusion Criteria: * Body weight between 50 kg and 90 kg with Body Mass Index \>18 kg/m² * Presence of body temperature ≥ 37.5°C or history of fever within the last 24 hours * Monoinfection with Plasmodium falciparum and parasitemia within the 100 to 200,000/microL Exclusion Criteria: * Hypersensitivity to quinoleines or artesunate * History or presence of any clinically significant disease or symptoms which, in the judgment of the investigator, might confuse the interpretation of the safety and efficacy information * Splenectomized patients * Laboratory parameters outside normal ranges * Presence of HBs antigen, anti-HCV antibodies and anti-HIV 1\&2 antibodies * Cardio vascular and Electrocardiogram parameters outside normal values * Presence of criteria of complicated malaria * Permanent vomiting * Previous treatment within 5 times the elimination half-life of any anti-malaria agents or with any marketed or investigational drugs (including St John's Wort) within 14 days before administration, or within 5 times the elimination half-life of that drug, whichever the longest, especially CYP3A and 2D6 main substrates * Positive results on urine drug screen for anti-malaria agents (aminoquinolines) * History of drug or alcohol abuse (alcohol consumption \> 40 grams/day ; i. e. 2.5 beers of 33cl with 5 degrees of alcohol) * Intention to use herbal medicine during the study period * Immunization injection within last 15 days The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.